Search Results 191-200 of 17800 for crohns disease

1. A Study of Vedolizumab in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) - Mayo Clinic

   A Study of Vedolizumab in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) ... Crohn's Disease (CD). Participation eligibility.

2. A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease - Mayo Clinic

   ... Crohn's Disease. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns.

3. An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease - Mayo Clinic

   ... Crohn's Disease. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns.

4. A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants with Moderately to Severely Active Crohn's Disease (CD) - Mayo Clinic

   At Week 14 (end of Induction Phase), participants achieving decrease of 70 points in Crohn's Disease Activity Index (CDAI) from baseline (CDAI-70 response) ...

5. Infliximab-abda (intravenous route) - Mayo Clinic

   Description. Infliximab-abda injection is used in adults to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, ...

6. Jana G. Al Hashash, M.D., M.S. - Doctors and Medical Staff - Mayo Clinic

   ... diseases (IBD), which include patients with Crohn's disease and ulcerative colitis. Prior to joining the Inflammatory Bowel Disease Center at Mayo Clinic ...

7. Growing mini-organs to find new treatments for complex disease - Mayo Clinic News Network

   It encompasses a group of inflammatory conditions that affect the digestive system such as Crohn's disease and ulcerative colitis. Symptoms of inflammatory ...

8. Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease - Mayo Clinic

   ... disease (IBD) has evolved over the last ten years. Evidence now suggests that the most effective therapy early in the course of Crohn's disease (CD) and ...

9. Examining the efficacy of recombinant zoster vaccination in patients with IBD - Mayo Clinic

   Individuals diagnosed with inflammatory bowel disease (IBD) have an increased risk of developing herpes zoster (HZ) and HZ-related complications.

10. Infliximab-dyyb (intravenous route, subcutaneous route) - Mayo Clinic

    Infliximab-dyyb injection is used to reduce the symptoms of moderate to severe active Crohn's disease and ulcerative colitis in adults and children who have ...